Impetigo

Scabies: UK facing unusually large outbreaks – and treatment shortages appear mostly to blame

Retrieved on: 
Friday, January 5, 2024

Outbreaks happen regularly – with an estimated 450 million cases occurring globally each year.

Key Points: 
  • Outbreaks happen regularly – with an estimated 450 million cases occurring globally each year.
  • But since the start of winter, outbreaks in the UK have been higher than normal.
  • While there a probably a few factors that can explain this spike, treatment shortages appear to be at the heart of it.
  • The skin rash is also more severe, with a crust over the surface of the infected area.
  • Itching may take up to a month to completely subside after treatment.

Outbreak causes

  • This means mites spread more easily in places where people come into close contact with each other for extended periods of time – such as schools, universities and prisons.
  • Residential care and nursing homes are particularly high-risk settings for scabies outbreaks, with vulnerable populations and staff members alike at risk of infection.
  • Another factor in the outbreak could be stigma against having scabies, with many people claiming the disease is caused by being unclean or a lack of bathing.
  • In reality, there’s no good evidence about a lack of washing being a risk factor.
  • While some evidence suggests that scabies incidence is higher in the winter, in reality outbreaks can happen at any time of the year.
  • Since September 2023, there’s been a shortage of both permethrin and malathion in the UK due to supply issues.

Preventing infection

  • If anyone has symptoms that might be scabies or another skin infection, such as itching and a rash or skin wounds, these should be reported to a doctor or healthcare provider as early as possible.
  • This is especially important if they have potentially been in close contact with a known case.
  • Scabies outbreaks can be brought under control – but diagnosis and treatment as early as possible is required for that to happen.


Michael Head has previously received funding from the Bill & Melinda Gates Foundation and the UK Department for International Development, and currently receives funding from Research England and the UK Medical Research Foundation.

Why is eczema sometimes treated with a diluted bleach bath? And what do I need to know before trying it?

Retrieved on: 
Wednesday, July 12, 2023

Diluted bleach baths are a common treatment doctors and nurses use for patients with more severe eczema.

Key Points: 
  • Diluted bleach baths are a common treatment doctors and nurses use for patients with more severe eczema.
  • It is important to note they may not replace other treatments and may not be suitable for everyone.

Germs can colonise damaged eczema skin

    • The person’s skin barrier becomes damaged and itchy, allowing germs to get established and cause even more problems.
    • The most common germ found in the damaged eczema skin is staphylococcus aureus.
    • Certain toxic materials known as “membrane-bound vesicles” are released by the staph germ, which causes an even more profound reaction in the skin, worsening the eczema.
    • Treating – or at least reducing – the amount of staph in the skin can help the eczema recover.

Reducing inflammation


    Researchers have also shown sodium hypochlorite can reduce inflammation in the skin. This is another reason the treatment is recommended. Eczema often involves a vicious cycle of inflammation, where redness and increasing itchiness leads to scratching and even more irritation. The skin breaks even more and the eczema worsens, leading to yet more inflammation. A diluted bleach bath can help break this vicious cycle.

You need to know what you’re doing

    • Diluted bleach bath instructions need to be tailored to the eczema, so don’t try it at home unless you’ve been advised by a dermatologist or doctor.
    • Dilution ratio: The bleach should be diluted in the bathwater to ensure it is safe for your skin.
    • A typical dilution ratio may be ½ cup (120 ml) of household bleach (containing 5-6% sodium hypochlorite) per 150 litres of lukewarm water.
    • However, the exact dilution ratio may vary based on the severity of your eczema, age and other factors.
    • Children may need less bleach in their bath.

LiVDerm Set To Launch Its Brand-New Online MOPD Foundations of Pediatric Dermatology Certificate Course

Retrieved on: 
Wednesday, June 7, 2023

This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.

Key Points: 
  • This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.
  • What makes this course even more appealing to busy health care professionals is the fact that it is fully online and self-paced.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

Potassium Permanganate Global Market to 2027: Initiatives Undertaken by Governing Authorities to Establish Water Treatment Plants Fuel the Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 11, 2023

Potassium permanganate is a chemical compound made by combining manganese oxide ore with potassium hydroxide.

Key Points: 
  • Potassium permanganate is a chemical compound made by combining manganese oxide ore with potassium hydroxide.
  • As it also helps in removing iron and hydrogen sulfide from well water, it finds extensive application in water treatment plants worldwide.
  • Additionally, the growing health awareness among individuals and numerous initiatives undertaken by governing authorities to establish water treatment plants are driving the market further.
  • The publisher provides an analysis of the key trends in each sub-segment of the global potassium permanganate market report, along with forecasts at the global and regional level from 2022-2027.

Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials

Retrieved on: 
Friday, April 7, 2023

DUBLIN, April 7, 2023 /PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 7, 2023 /PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dermatology Partnering 2016-2023: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.
  • The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering dermatology deals.
  • The Global Dermatology Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 700 dermatology deals.

Mednow Supports Expanded Scope of Practice for Ontario Pharmacists

Retrieved on: 
Monday, January 23, 2023

Mednow Inc (TSXV: MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy is supportive of the new expanded scope of practice for Ontario pharmacists.

Key Points: 
  • Mednow Inc (TSXV: MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy is supportive of the new expanded scope of practice for Ontario pharmacists.
  • As of January 1st, pharmacists in Ontario are now able to better support patients by assessing and prescribing treatment for 13 minor conditions.
  • "We are thrilled to see the expanded scope of practice for pharmacists in Ontario," said Ali Reyhany, CEO and Co-Founder of Mednow.
  • The expanded scope of practice for Ontario pharmacists will allow Mednow to expand its virtual care program to include pharmacist-led prescribing.

Dettol Pro Solutions Shares How to Help Prevent Spread of Strep A Via Proper Cleaning Protocols and Product Selection

Retrieved on: 
Wednesday, January 18, 2023

GAS infections often present as a mild sore throat ('strep throat') and skin/soft tissue infections such as impetigo and cellulitis1.

Key Points: 
  • GAS infections often present as a mild sore throat ('strep throat') and skin/soft tissue infections such as impetigo and cellulitis1.
  • Dettol Pro Solutions, which consists of a team of in-house virologists, microbiologists and medical scientists, was launched in the UK last year.
  • Dettol Pro Solutions’ products are demonstrated to kill 99.9% of bacteria and enveloped viruses including Streptococcus A, Covid-19 and Influenza6.
  • For further information and advice from Dettol Pro Solutions, please visit https://www.reckittpro.co.uk .

ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development

Retrieved on: 
Thursday, January 12, 2023

Their distributed team of digital marketing experts specializes in scaling out personalized digital marketing growth systems that have helped produce over $1 Billion in sales revenue online for dozens of brands to date.

Key Points: 
  • Their distributed team of digital marketing experts specializes in scaling out personalized digital marketing growth systems that have helped produce over $1 Billion in sales revenue online for dozens of brands to date.
  • “We’re very honored and excited to be working with ViaDerma to help grow the brand and business online.
  • The INTENT SCIENCES team will be working closely with ViaDerma management to help grow the B2B & DTC demand side for ViaDerma licensing and lead product Vitastem Ultra.
  • ViaDerma President & CEO, Dr. Chris Otiko said, “We are thrilled to bring INTENT SCIENCES in at this time to help us move forward in this new year.

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

Retrieved on: 
Friday, December 16, 2022

WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022.

Key Points: 
  • WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022.
  • Stockholders re-elected board nominee Loretta M. Wedge to the Biofrontera Inc. Board of Directors as Class I director to serve until the 2025 Annual Meeting of Stockholders.
  • Stockholders approved an amendment to the Biofrontera Inc. 2021 Omnibus Incentive Plan to increase the number of shares authorized for issuance under the plan by 2,589,800 shares.
  • Stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the 2022 fiscal year.

Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference

Retrieved on: 
Wednesday, November 30, 2022

WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmarks 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.

Key Points: 
  • WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmarks 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.
  • Erica Monaco, Chief Executive Officer, and Hermann Lbbert, Executive Chairman of Biofrontera Inc. will be meeting with registered investors in one-on-one meetings and small-group sessions.
  • Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics.
  • The Companys licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.